Latest / Peptides Weekly / Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully…

Transcript

Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully… · Peptides Weekly

• 0:00
  Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. This is Peptides Weekly, episode 4. Education and evidence, never-dosing advice. Political wire quotes the Washington Post on a drafting process, which is policy reporting rather than a patient trial. The paper's account says compounding pharmacies could hand out some of those peptides as marketed treatments and as wellness products.
• 0:26
  effects.
• 0:27
  Federal health officials are still writing the regulations around them.
• 0:31
  On October 1st, this show was tracking compounding rules, and the new piece is that temporary
• 0:37
  sale draft for products the headline still calls unapproved.
• 0:41
  Stock Twits reported an FDA advisory panel backed four peptides, a panel action rather
• 0:47
  than a published patient study.
• 0:49
  That item also tied the backing to an overnight rise in hymns' shares and a short bit by
• 0:55
  Martin Shkreli. Medical economics, the same day, said the FDA would convene an expert panel
• 1:01
  on wider peptide access. Those reports describe meetings, backing, and a share move, not a measured
• 1:08
  health outcome. The ASCO post reported a link between GLP1 receptor agonist use and lower colorectal
• 1:16
  cancer risk among people with inflammatory bowel disease. The Sacramento Bee and the Raleigh News
• 1:22
  an observer, both ran consumer pieces on oral peptide strips.
• 1:27
  The B says the strips promised needle-free delivery and puts the FDA and researcher view as
• 1:32
  the question in play.
• 1:34
  The news and observer describes dissolving films and asks how the strips work.
• 1:39
  In the text here, neither piece is a human efficacy measurement.
• 1:43
  Food Navigator reported that weight regained after GLP1 treatment could be mitigated by
• 1:49
  diet.
• 1:49
  it.
• 1:50
  That is a possibility stated in a headline, not a randomized trial result with a number
• 1:55
  attached.
• 1:56
  This week's spotlight is collagen peptides taken by mouth, studied as supplements and
• 2:01
  in one paper as a neutrophosimetic ingredient, not as a named approved drug.
• 2:07
  A 2015 cosmetic dermatology paper says earlier preclinical work suggested these fragments
• 2:13
  can support the skin barrier, prompt collagen and hyaluronic acid synthesis, and encourage
• 2:19
  fibroblasts to grow and move. In human skin
• 2:23
  plants, an X vivo setup, the peptides induced collagen and glycosaminoglycan
• 2:28
  production. That is a tissue finding, not a map of digestion in a living person.
• 2:34
  The same paper reports two placebo-controlled human trials in which oral
• 2:38
  supplementation raised skin hydration after eight weeks by corneometry.
• 2:44
  Dermal collagen density rows and network fragmentation fell after four weeks on
• 2:49
  ultrasound and reflectance confocal microscopy, and both structural changes were still there
• 2:55
  at 12 weeks. A separate randomized placebo-controlled trial enrolled Korean adults aged 19 to 60
• 3:02
  with mild to moderate hair damage and no alopecia. After 24 weeks of a low molecular weight collagen
• 3:09
  peptide called GT, gloss improved against placebo on a gloss meter and on scanning electron microscopy.
• 3:16
  Elasticity improved too, judged by tensile strength and hair diameter, and scalp elasticity
• 3:23
  rose in the treated group.
• 3:25
  Participants also rated gloss, elasticity, thickness, texture, fullness, and appearance
• 3:31
  as better.
• 3:32
  No treatment-related adverse events were observed, and the authors called the course
• 3:36
  safe and effective for hair condition in that group.
• 3:40
  The abstract notes earlier preclinical work in which low molecular weight fish collagen
• 3:45
  peptides promoted hair regrowth through proliferative signals and less inhibitory signaling,
• 3:51
  and it says clinical efficacy for hair damage had not been clearly shown before this trial.
• 3:56
  This human study measured damage and shine, not regrowth in alopecia.
• 4:01
  A pilot randomized double-blind trial followed 22 premenopausal women, 18-35, who ran at least
• 4:09
  35 miles a week. For four weeks they took collagen peptides or an isocholoric
• 4:14
  maltodextreme placebo, with labs in the early follicular phase. P1NP, a bone
• 4:21
  formation marker, showed a group by time interaction at P equals 0.04. It rose
• 4:27
  on collagen and did not change on placebo. CTX1, a breakdown marker, had no
• 4:34
  significant interaction, P equals 0.13.
• 4:38
  IL-6 showed a significant interaction at P equals 0.03.
• 4:43
  The results text both reports a significant S-rankel interaction
• 4:47
  at P equals 0.046, and later says no significant interaction
• 4:52
  for S-rankel, osteoprategorin, or their ratio,
• 4:56
  so that osteoclast signal is not cleanly established.
• 5:00
  The discussion still says the short course raised a formation marker, shifted osteoclast-related
• 5:06
  signaling, and lowered IL-6, and it asks for larger trials with structural bone outcomes.
• 5:13
  Another randomized double-blind trial followed 53 men with sarcopenia, mean age 72.2 years,
• 5:20
  standard deviation 4.68.
• 5:23
  All of them did 12 weeks of guided resistance training, three sessions a week, plus either
• 5:28
  collagen peptides or a silica placebo.
• 5:32
  Finisher as a whole gained fat-free mass, bone mass, quadricep strength, and sensory motor
• 5:38
  control, and lost fat, each at p less than 0.01.
• 5:43
  The collagen arm moved further, fat-free mass up 4.2 kg versus 2.9.
• 5:49
  Strength up 16.5 Newton meters versus 7.3.
• 5:54
  Fat mass down 5.4 kg versus 3.5.
• 5:57
  each comparison P less than 0.05. That extra change belongs to training plus
• 6:04
  supplement, not to the peptide by itself. Across this set, fracture prevention is
• 6:09
  not shown, alopecia regrowth is not shown, and a blood marker is not a clinical
• 6:14
  bone outcome. Only the hair trial states a safety result, and none of these
• 6:19
  abstracts test whether a retail bottle matches the study material. One thing
• 6:24
  Being worth knowing is that a cancer risk link for GLP1 drugs in inflammatory bowel disease
• 6:30
  does not mean those drugs have been shown to prevent cancer.
• 6:34
  Another is that the collagen human trials measure skin structure, hair condition, bone markers,
• 6:40
  and training-related body composition, which is not the same as treating a disease.
• 6:45
  A third is that temporary sale drafts and advisory panel backing are about access and process,
• 6:51
  not prove those peptides work in people. That's peptides weekly. This show is
• 6:57
  education, not medical advice. Talk to your own clinician before acting on
• 7:01
  anything you heard. I'm Patrick in Vancouver. See you next week. And before you
• 7:07
  go, this show is part of the Nerra network, a family of daily podcasts on tech,
• 7:12
  science, and markets. Each one a short, sharp briefing you can finish on the
• 7:17
  commute. If today earned its place in your feed, here's your next listen. Offshore North,
• 7:23
  Offshore Ocean Racing explained every Monday with a Canadian angle. Find every show free
• 7:29
  at nerranetwork.com. If you follow more than one of our shows, Narra Daily stitches the
• 7:35
  whole network into one morning listen, free with chapters at nerranetwork.com, Narra Daily.
• 7:42
  This episode used AI voice synthesis of my voice.
• 7:46
  Editorial selection and analysis are my own.